EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints

Mingyue Li, Zhonglong Guo, Yingjie Qiu

Statistics in Medicine · 2025

DOI: 10.1002/sim.70098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Mingyue Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Research Design, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A primary objective of oncology dose‐finding trials for novel therapies is to determine an optimal biological dose (OBD) that is both tolerable and therapeutically beneficial for patients in subsequent clinical trials. These new therapeutic agents are more likely to induce multiple low‐ or moderate‐grade toxicities rather than dose‐limiting toxicities. Additionally, efficacy is evaluated comprehensively, differentiating between complete remission and partial remission, as well as incorporating continuous efficacy endpoints. This important issue was highlighted in the American Statistical Association (ASA) Biopharmaceutical (BIOP) Section open forums and was a significant consideration of the FDA's “Project Optimus.” We proposed the UNITED design, a unified, transparent, and efficient Phase I/II trial design to incorporate toxicity and efficacy grades and types, as well as continuous efficacy responses, into dose‐finding and optimization. The UNITED design can handle binary, quasi‐binary, continuous, and mixed toxicity and efficacy endpoints. We further extended the UNITED design, referred to as TITE‐UNITED, to accommodate delayed toxicity and efficacy outcomes. Simulation studies showed that the UNITED and TITE‐UNITED designs have desirable operating characteristics, performing comparably to or better than existing designs. A user‐friendly software is available for practical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicClinical Trials, Phase II as TopicResearch DesignAntineoplastic AgentsHumansDose-Response Relationship, DrugMaximum Tolerated DoseComputer SimulationEndpoint DeterminationUnited StatesModels, StatisticalTreatment Outcome

Stichwörter der Autor:innen

Phase I/II trialadaptive designdelayed outcomesefficacy gradesoptimal biological dosetoxicity grades

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Co-Innovation Center for Sustainable Forestry in Southern China, College of Life Sciences, Nanjing Forestry University, Nanjing, China.
  • Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Li, M., Guo, Z., & Qiu, Y. (2025). UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints. Statistics in Medicine. https://doi.org/10.1002/sim.70098

Vancouver

Li M, Guo Z, Qiu Y. UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints. Statistics in Medicine. 2025. doi:10.1002/sim.70098

BibTeX
@article{Li2025,
  author = {Li, Mingyue and Guo, Zhonglong and Qiu, Yingjie},
  title = {UNITED: A Unified Transparent and Efficient Phase I/II Trial Design for Dose Optimization Accounting for Ordinal Graded, Continuous and Mixed Toxicity and Efficacy Endpoints},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70098}
}
Kostenlos starten →